Literature DB >> 29109093

DEK-NUP214-Fusion Identified by RNA-Sequencing of an Acute Myeloid Leukemia with t(9;12)(q34;q15).

Ioannis Panagopoulos1, Ludmila Gorunova2, Synne Torkildsen2,3, Geir E Tjønnfjord3,4, Francesca Micci2, Sverre Heim2,4.   

Abstract

BACKGROUND/AIM: Given the diagnostic, prognostic, biologic, and even therapeutic impact of leukemia-associated translocations and fusion genes, it is important to detect cryptic genomic rearrangements that may exist in hematological malignancies. CASE REPORT: RNA-sequencing was performed on an acute myeloid leukemia case with the bone marrow karyotype 45,X,-Y,t(9;12) (q34;q15)[16].
RESULTS: The DEK-NUP214 and PRRC2B-DEK fusion genes were found. Reverse transcriptase polymerase chain reaction together with direct sequencing verified the presence of both. Fluorescence in situ hybridization showed that the DEK-NUP214 fusion gene was located on the 6p22 band of a seemingly normal chromosome 6.
CONCLUSION: RNA-sequencing proved to be a valuable tool for the detection of a fusion of genes DEK and NUP214 in a leukemia that showed cryptic cytogenetic rearrangement of chromosome band 9q34. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; DEK; DEK-NUP214 fusion gene; NUP214; PRRC2B; PRRC2B-DEK fusion gene; RNA-sequencing

Mesh:

Substances:

Year:  2017        PMID: 29109093      PMCID: PMC6070322          DOI: 10.21873/cgp.20053

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  26 in total

Review 1.  Molecular diagnosis of leukemia.

Authors:  Joanne Mason; Michael Griffiths
Journal:  Expert Rev Mol Diagn       Date:  2012-06       Impact factor: 5.225

2.  t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Authors:  Julie Damgaard Sandahl; Eva A Coenen; Erik Forestier; Jochen Harbott; Bertil Johansson; Gitte Kerndrup; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Jean-Michel Cayuela; Lucy Chilton; Maarten Fornerod; Valérie de Haas; Christine J Harrison; Hiroto Inaba; Gertjan J L Kaspers; Der-Cherng Liang; Franco Locatelli; Riccardo Masetti; Christine Perot; Susana C Raimondi; Katarina Reinhardt; Daisuke Tomizawa; Nils von Neuhoff; Marco Zecca; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Henrik Hasle
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

Review 3.  Genetic Basis of Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Authors:  John S Welch; Peter Westervelt; Li Ding; David E Larson; Jeffery M Klco; Shashikant Kulkarni; John Wallis; Ken Chen; Jacqueline E Payton; Robert S Fulton; Joelle Veizer; Heather Schmidt; Tammi L Vickery; Sharon Heath; Mark A Watson; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

Review 6.  SNP array analysis in hematologic malignancies: avoiding false discoveries.

Authors:  Stefan Heinrichs; Cheng Li; A Thomas Look
Journal:  Blood       Date:  2010-03-19       Impact factor: 22.113

7.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Authors:  S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

Review 8.  Hypereosinophilic Syndrome.

Authors:  Casey Curtis; Princess Ogbogu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

9.  Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.

Authors:  Carl Sandén; Malin Ageberg; Jessica Petersson; Andreas Lennartsson; Urban Gullberg
Journal:  BMC Cancer       Date:  2013-09-27       Impact factor: 4.430

10.  Comparison between karyotyping-FISH-reverse transcription PCR and RNA-sequencing-fusion gene identification programs in the detection of KAT6A-CREBBP in acute myeloid leukemia.

Authors:  Ioannis Panagopoulos; Synne Torkildsen; Ludmila Gorunova; Anne Tierens; Geir E Tjønnfjord; Sverre Heim
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

View more
  2 in total

1.  RUNX1-PDCD6 fusion resulting from a novel t(5;21)(p15;q22) chromosome translocation in myelodysplastic syndrome secondary to chronic lymphocytic leukemia.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Eva-Marie Jacobsen; Kristin Andersen; Francesca Micci; Sverre Heim
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

2.  Novel GTF2I-PDGFRB and IKZF1-TYW1 fusions in pediatric leukemia with normal karyotype.

Authors:  Ioannis Panagopoulos; Marta Brunetti; Margrethe Stoltenberg; Rønnaug A U Strandabø; Julie Staurseth; Kristin Andersen; Ilyá Kostolomov; Tarjei S Hveem; Susanne Lorenz; Tove Anita Nystad; Trond Flægstad; Francesca Micci; Sverre Heim
Journal:  Exp Hematol Oncol       Date:  2019-05-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.